The parent company of Ojai Community Bank has increased its net income 52 percent year to date for the nine months ending Sept. 30, according to OCB Bancorp’s third-quarter report. OCB Bancorp, also the parent company of Santa Barbara Community Bank, Ventura Community Bank and Santa Paula Community Bank, increased its total loans by $48 Read More →
A Delaware bankruptcy court has approved six of the original seven bids for former Haggen stores throughout the Tri-Counties. The Washington-based grocery chain announced on Nov. 25 that the court approved the sale of 47 of its 164 stores. Pending successful deals with landlords, Albertsons will take over its former location at 1500 N. H Read More →
Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →
Santa Barbara software developer QAD Inc. saw revenues decrease slightly in the third quarter of fiscal year 2016. Revenues at QAD decreased from $74 million to $68 million. Net income for the company was $2.6 million, or 14 cents per share. That missed analyst estimates of 18 cents per share. In recent years, QAD has Read More →
NRG Energy updated the application for its new peaker power plant in Oxnard on Nov. 19. In an updated filing with the California Public Utilities Commission, NRG said it would demolish the current power plant and a cooling tower on the site if the new Puente Power Project is approved by the commission. Dave Read More →
When California passed AB 939 in 1989, the mandatory waste diversion goals looked lofty and unreachable. But Harrison Industries of Ventura stepped up with a unique plan to provide all of its customers in Ventura and Santa Barbara counties with waste bins that allowed them to separate trash and recyclables. Twenty-five years later, Gold Read More →
Thousand Oaks-based Amgen scored another major victory Nov. 19. European regulators approved experimental drug Kyprolis on Thursday for patients who have received at least one prior treatment for multiple-myeloma. Kyprolis was the cornerstone of Amgen’s $10.4 billion buyout of Onyx Pharmaceuticals in 2013. Multiple-myeloma is a form of blood cancer that forms in plasma cells Read More →